Body composition and sarcopenia seem to be prognostic of enhanced chemotherapy and targeted therapy toxicity [7, 8, 10, 11, 13], and more recently with immune checkpoint inhibitors such as anti-CTLA-4 (ipilimumab) [12]. The gene discussed is CTLA4; the disease is sarcopenia.